# The TCRA High Finance Deal with a Heart

TCRA will save the lives of **160,000** Rh babies and prevent **100,000** children living with cerebral palsy. To educate someone to understand how it will work, to believe in it and work for it we will involve our student in an open discussion session where they hear **the following facts and arguments** of TCRA explained and expanded. Our subjects will hear a lot more in discussion than what is in each bullet and will have questions answered. And realize that they personally can contribute to saving the Rh babies.

**SUMMARY**
Top PE firm Blackstone (BX) will be induced by a huge, immediate ownership of **$100 billion** in future cash flow, to do a novel LBO of TCRA, whereby they have **Big 5** companies, *Roche, Siemens, Abbott, Hanover and Amazon One Medical*, accept **30%** of TCRA shares cost free, induced by the immediate ownership of **$300 billion** in future cash flow. These **Big 5** shareholders will immediately announce separately that they will convert their client clinical labs across the world, running **66%** of world lab test volume, from their current **TLA** clinical analyzers to **DLA**, which is based on TCRA's formidable worldwide patent portfolio. This creates the prospect of **$1 trillion** in royalties paid to TCRA on the **$8 trillion** revenues clinical labs will earn from lab tests run on DLA**, the most assured revenues in any industry**. This will immediately make TCRA into a huge important company valued at **$300 Billion**, given five Fortune 500 size companies are major shareholders, with a bold mission to revolutionize the world's clinical labs. BX will immediately engage top underwriters *Goldman, Morgan Stanley and JPMorgan*, to to raise **$30 Billion** at a **$300 billion** valuation selling TCRA shares in private markets.

This TCRA **high finance deal with a heart** , a truly spectacular accelerated LBO, will provide WIRhE with an immediate **$20 billion** endowment enabling saving of **160,000** Rh babies lives and preventing **100,000** cases of cerebral palsy annually in perpetuity. **$500 Billion** in cash flow will go to nonprofit organizations.

## Frame 1 TCRA Facts and Issues

1. The TCRA high finance deal is a perfectly sound high finance plan based on **enormous new royalty revenues** to be paid to TCRA by the **$293 billion** global clinical lab industry when it adopts DLA. Global clinical labs will earn **$8 trillion** from clinical lab tests done on automated clinical analyzers using TCRA patents. An extraordinary

confluence of circumstance in the global lab industry will let TCRA, a small California startup LLC, see its DLA patents used to collect **$1 trillion** in future royalty cash flow, **all profit**, paid by global clinical labs to TCRA over the life of its DLA patents.

2. O**ur single point goal** is to make TCRA shares worth **$300 billion** in the very short term, (like the SpaceX IPO!) **once the Big 6 large powerful companies,** *Siemens, Roche, Abbott, Beckman Coulter, Amazon One Medical* and *Blackstone* **become TCRA's major shareholders**. And publish a **'prospectus'** predicting **$1trillion** in royalty revenue for TCRA, EBITDA **98%,** over **20** years, from tapping **$8 trillion** revenues of the clinical lab industry, This **new capital structure** will **instantly** make TCRA into a powerful new company with enormous commercial, financial and legal heft.

3. The best way for TCRA to gain these powerful new shareholders is for a leading private equity firm like **Blackstone** to establish and manage the new capital structure of TCRA. By using its resources, tenacity and skills to get all the parties on board the plan BX will get **10%** of TCRA shares, $**100 billion** in future cash flow. BX's leaders, Steven Schwarzman, Jon Gray and Tony James are all very partial to deals that are a **new idea, big, shorter term and very profitable**. An LBO of TCRA ticks all these boxes in spades.

4. This capital restructuring of TCRA requires Blackstone to invite **5** selected companies, *Siemens, Roche, Abbott, Beckman Coulter* and *Amazon One Medical* to accept **30%** of TCRA shares, inducing them with the prospect of **$300 billion** in royalties, at no cost. The deal thereby incentivizes the **Big 6** TCRA shareholders with the prospect of sharing instant ownership of $**400 billion** in future cash flow with minimal risk, i.e. no equity investment or debt. **50%** of TCRA shares will be placed in a DAF to fund WIRhE and other philanthropy. TCI will retain **10%**.

5. Why the TCRA deal will work: **90 percent** of clinical lab tests, **66 percent** of the world's lab test volume, are now run on highly automated TLA clinical analyzers. manufactured by the entrenched oligopoly of **4** powerful Fortune 500 sized companies: Siemens, Roche, Abbott and Hanover, the Big 4. They took the wrong direction in clinical lab automation **30 years ago**, developing so-called TLA, Total Lab Automation. leaving clinical labs just **50%** automated, half the labor still manual. Further improvement in the level of automation

is impossible with the TLA approach. After **30 years** TLA automation has reached a dead end.

6. **DLA**, Dark Lab Automation using Team Conveyer technology is a relatively simple straightforward way to automate the manual work still not done by TLA lab automation. This different approach should have been taken **30 years** ago. TCRA owns a formidable portfolio of DLA patents, allowed and pending, in the United States, China, Europe, Korea, Canada, Japan, Australia, and Hong Kong.

7. All **Big 6** TCRA shareholders will confidently declare their intent to convert the world's clinical labs from TLA to DLA, taking advantage of this extraordinary opportunity to **instantly** achieve **gain of value** for TCRA to **$300 billion**.

8. The BX investment committee will quickly realize that a unique confluence of circumstances in the clinical lab industry is **amazing serendipity.** They will not let their part in the deal slip for lack of imagination; they will rejoice that BX fortunately is at the right place at the right time with the right resources. **$100 billion** in future cash flow with no investment is a very worthwhile return for BX.

9. To do the LBO of TCRA: after preliminary investigations, the BX deal team will report back to their investment committee strongly recommending that BX's role in the TCRA deal is to recruit the **5** selected companies as new shareholders for TCRA and just manage the LBO, **not** do the whole LBO all by themselves. What can be done must be done, to make TCRA as valuable as possible, and fast because hhge TCRA gain of value will be caused by **Big 6** announcements well ahead of any business activity. Ironically TCI owning **10%** of TCRA will be worth more than owning **100%** of TCRA without the new shareholders.

10. The Blackstone deal team that studies the TCRA deal understands that the immediate increase of company value for TCRA depends almost entirely on the prestige, track record, commercial and legal strength of the new shareholders of TCRA. That is why Blackstone will invite this 'dream team' of select new 'startup founders' with absolute credibility to launch the new TCRA with great verve.

11. **To understand the royalty flow**: The Big 4 clinical lab automation manufacturer oligopoly, Siemens, Roche, Abbott, Beckman Coulter,

will be joined by Amazon One to become the Big 5 DLA manufacturer oligopoly. They will announce that each one of them will develop their own line of DLA clinical lab automation systems, in competition, using the TCRA intellectual property.

12. Each **Big 5** will publicly announce with fanfare that their company will **manufacture, sell and install** superior automated DLA clinical lab systems across the world, replacing their current inferior TLA systems in their own client labs worldwide, which currently run 66% of the world's lab test volume.

13. The **Big 6** will claim with a high degree of confidence that they can have global clinical labs use TCRA intellectual property and make them pay **$1 trillion** in royalties to TCRA on revenues for use of the newly installed DLA automation systems. Cost savings from DLA will cancel the added cost of the royalties for clinical labs.

14. The company value of TCRA will immediately rise to **$300 billion o**nce the **Big 6** confidently announce that they can create **$1 trillion** in future royalty cash flow for TCRA paid by global clinical labs, all profit,

15. Immediately post DLA announcements Blackstone will engage top underwriters, *Morgan Stanley, JP Morgan and Goldman* to raise **$30 billion** at a company valuation of **$300 billion** selling newly valuable TCRA shares in private markets. **$20 billion** for a WIRhE endowment, and **$10 billion** cash for the shareholders of TCRA

16. TCRA shareholders, and shareholders gaining shares from the DAF, will receive more than **$900 billion** in royalty cash flow over **20 years**.

17. The side benefits of the TCRA deal: protecting the **260,000** Rh babies annually in perpetuity and creating **$500** billion in cash flow for philanthropic causes.

----------------------- ----------------------------------------------------------------

**Frame 2 TCRA Facts and Issues**

7/24/2026 10:49 AM

TCRA is a very bold plan that arouses extreme caution. The main reason – they don't know that the TCRA deal is geared to making TCRA valuable quickly by installing powerful new shareholders in TCRA upfront.

O**ur single point goal** is to make TCRA shares worth **$300 billion** in the very short term, (like the SpaceX IPO!) by giving TCRA a special place in the future of the clinical lab industry. Here's the key. **TCRA will become very valuable once the Big 6 large powerful companies,** *Siemens, Roche, Abbott, Beckman Coulter, Amazon* and *Blackstone One Medical* **become TCRA's major shareholders**. And publish a **'prospectus'** predicting **$1trillion** in royalty revenue for TCRA, EBITDA **98%,** over **20** years, from tapping **$8 trillion** revenues of the clinical lab industry.

**How do we get Big 8 to become TCRA's major shareholders?**

First, **50%** of TCRA shares will be placed in a DAF to be used to fund WIRhE to save the lives of **160,000** Rh babies and prevent **100,000** children growing up with cerebral palsy from Rh Disease (RDFN). And, **$500 billion** in future cash flow will be available for other charitable causes.

Then, **40%** of TCRA shares, **$400 billion** in future cash flow, will be offered to the **Big 6** at no cost to induce them to become the major shareholders of TCRA, immediately increasing the valuation of TCRA to **$300 billion.** It will be very profitable with no risk for all **Big 6** to become the 'founding team' that make TCRA's first business moves.

The best way to get **6** big shareholders on board quickly is to induce a big PE firm like Blackstone to manage bringing the **Big 5** to join BX as the major TCRA shareholders. We have to figure out **what deal** we offer BX that they will jump on and make it happen in their own huge interest BX making the best deal for themselves will make it the best deal for TCRA. We must make Blackstone understand how profitable an 'ILBOW' of TCRA will be for Blackstone.

The simplest idea for royalty distribution is DAF **50%** BX **10%** TCI **10%** and let BX figure out how to share **the remaining 30%** with each of the Big **5** to induce them to come onboard. Deals will go from carrot to stick when the first clinical lab automation manufacturer joins, as the others preserving their clinical lab automation market share will become existential.

**How do we get access to Blackstone?**
We need to and make it worthwhile for people and institutions who have access to BX to provide us with access. We can use TCRA shares as a currency to pay people and institutions who will help make TCRA succeed.

One plan is to find individuals who will identify large nonprofits with worthy causes and contact their fundraising offices to ask the nonprofits to accept a donation of TCRA shares that will be worth **billions of dollars** if the TCRA deal succeeds. In return the nonprofits help by involving the Rh Cap Club billionaires on their boards to give us access to BX. Commissions are paid in TCRA share, **1%** of the share numbers they get nonprofits to accept, redeemed with cash from selling TCRA DAF shares when they become valuable.

Another plan is to give TCRA shares to individuals who make donations to WIRhE and also agree to help.

Another plan is to canvas executives of the three big oligopolist plasma companies that market anti-D immunoglobulin, *CSL-Behring, Grifols and Kedrion*, to provide TCRA with access to BX executives. These plasma companies stand to double their RhIG market if the TCRA deal succeeds.

Another plan is to canvas executives of the three big delivery companies, *Fedex. DHL and UPS*, with whom WIRhE must contract with to deliver **10 million** doses of RhIG to labor rooms and home birth sites across the Global South. **$500 million** in new delivery revenues if the TCRA deal succeeds. Get their help with access to BX.

Another plan is to get a story written in the financial press that will make billionaires aware of their opportunity to save or enhance **260,000** Rh babies' lives every year in perpetuity.

There is a way to extend the cash flow to TCRA long after the term of the patents with **MaaS,** and so make TCRA even more valuable in the short term. Let's look at this idea. The alternative business plan for TCRA, a startup with a VC, would take years and it's fraught, and would probably never fund WIRhE.

---------------------------------------------------------------------------------------